Advertisement


Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab

2023 ASCO Annual Meeting

Advertisement

Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses phase I/II results on the efficacy of nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma. The study found that, for this rare and aggressive skin cancer, nivolumab showed clinical activity in advanced disease. However, these results from CheckMate 358 do not suggest an additional benefit with ipilimumab added to nivolumab (Abstract 9506).

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Shailender Bhatia: Merkel cell carcinoma is a very aggressive skin cancer. There are two known causes of this cancer, one is the Merkel cell polyoma virus, and the other is ultraviolet radiation exposure. Now, because of both of those causes, the cancer turns out to be very immunogenic. In the virus-positive cancers, that's due to the presence of the non-self viral antigens, and in UV exposure-related cancer, it is the high tumor mutational burden, which leads to expression of neoantigens. Now, because of this immunogenicity, there has been a lot of interest in trying different immunotherapies. There are three immunotherapies that are already FDA approved, avelumab, pembrolizumab, and most recently, retifanlimab, and these drugs work very well in a subset of patients with metastatic disease. The response rates are high, around 50% or so, and the responses tend to be very durable. However, there's a significant proportion of patients who do not respond, and the study that I'm going to be talking about today essentially pertains to improving the response rates in the frontline setting. Just to provide a little bit of background for our study, there was a recent study, that was published by the Moffitt Group, that also looked at these drugs, nivolumab in combination with ipilimumab, and they looked at a cohort of 24 patients who had never had immunotherapy before, and they reported an astounding response rate of 100%. Everybody in that study responded, suggesting that the combination of NIVO and IPI may actually be a way to have a higher response rate in the frontline setting. So today, I'm going to present the results of our study, which is using the same schedule of NIVO and IPI as the Moffitt study, but was done several years prior to the Moffitt study that was completed. So just for the background of our study, we had two cohorts, one was nivolumab monotherapy, and the other one was NIVO plus IPI. Again, the dose in the NIVO plus IPI was NIVO given every two weeks, at the standard dose of three milligram per kilogram, and IPI was given at one milligram per kilogram every six weeks, similar to the Moffitt study. So the important thing to note is that our study was a non-randomized study. The first cohort just investigated NIVO monotherapy, and when that cohort was full, the other cohort opened up, which investigated NIVO plus ipi. So in a way, today, we'll be comparing the results of these two cohorts, but just to caution that this was a non-randomized study. Importantly, our study did not allow prior immunotherapy, so these are all immunotherapy-naive patients. A very small proportion got prior chemotherapy, but that does not change the main message of our study. Just to summarize the results, similar to other PD-1 and PD-L1 agents, we saw a very high response rate in both cohorts. The response rate was around 60% in the NIVO cohort, and 58% in the NIVO plus IPI cohort. In the subset of patients who were previously untreated, the response rates were somewhat higher than those numbers. Now, surprisingly, and in contrast with the Moffitt study, we did not see a significant increase in the response rates or other efficacy outcomes with NIVO plus IPI. So as I said, the response rate was almost similar, but importantly, the progression-free survival, the overall survival, and even the duration of response data, actually tended to be inferior in the NIVO plus IPI cohort, which was somewhat surprising. So just to dive into some of the reasons for why that might have been, we looked at the toxicity data. Actually, the toxicity data suggests that we were getting more immune activation in patients who got NIVO plus IPI. The rate of grade three or higher adverse events was 46% in the NIVO plus IPI cohort, and was 28% in the NIVO cohort. So we were getting more immune activation, but for some reason, that immune activation did not translate into improved efficacy outcomes. So the results, again, are in sharp contrast with the Moffitt study, which suggested 100% response rate with NIVO plus IPI. So where does our data and Moffitt data lead us? I think we have to just keep in mind that all of these studies in an uncommon cancer like Merkel cell have very small number of patients, so the results could be biased by selection biases and other confounders, so we just have to be careful in not overinterpreting the results. But nevertheless, I think it's important to state that there is this question of using combination immunotherapy to improve upfront responses in an immunogenic cancer like Merkel cell, and I think there is a need for doing a more rigorous and larger study to answer this question more definitively.

Related Videos

Lymphoma

Catherine C. Coombs, MD, on B-Cell Malignancies and Long-Term Safety of Pirtobrutinib

Catherine C. Coombs, MD, of the University of California, Irvine, discusses prolonged pirtobrutinib therapy, which continues to demonstrate a safety profile amenable to long-term administration at the recommended dose without evidence of new or worsening toxicity signals. The safety and tolerability observed in patients on therapy for 12 months or more were similar to previously published safety analyses of all patients enrolled, regardless of follow-up (Abstract 7513).

Colorectal Cancer

Smitha Krishnamurthi, MD, and Deb Schrag, MD, MPH, on Rectal Cancer: New Findings on Chemoradiation, Chemotherapy, and Excision

Smitha Krishnamurthi, MD, of the Cleveland Clinic, and Deb Schrag, MD, MPH, of Memorial Sloan Kettering Cancer Center, discuss phase III findings from the PROSPECT trial, which showed FOLFOX chemotherapy with selective use of radiation therapy and sensitizing fluoropyrimidine (5FUCRT) is noninferior to 5FUCRT for the neoadjuvant treatment of patients with locally advanced rectal cancer, prior to low anterior resection with total mesorectal excision (Abstract LBA2).

Leukemia
COVID-19

Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax

Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax is not superior to ibrutinib plus obinutuzumab for treatment-naive older patients with chronic lymphocytic leukemia (CLL) in the setting of the COVID-19 pandemic. Long-term follow-up will determine whether there are advantages to obinutuzumab plus venetoclax, with special attention to measurable residual disease and therapy discontinuation (Abstract 7500).

Bladder Cancer

Christian Pfister, MD, PhD, on Bladder Cancer: New Overall Survival Data on Perioperative Chemotherapy

Christian Pfister, MD, PhD, of Rouen University Hospital, discusses phase III results from the VESPER trial, which showed that dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin provided a better overall survival rate at 5 years and improved disease-specific survival compared with gemcitabine as perioperative chemotherapy in patients with muscle-invasive bladder cancer (Abstract LBA4507). 

Gynecologic Cancers
Immunotherapy

Bobbie J. Rimel, MD, Isabelle L. Ray-Coquard, MD, PhD, on Cervical Squamous Carcinoma: Neoadjuvant Nivolumab Plus Ipilimumab

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Isabelle L. Ray-Coquard, MD, PhD, of Centre Léon Bérard and the University Claude Bernard Lyon Est, discuss findings from the COLIBRI trial, which showed that, for patients with cervical squamous cell carcinoma, neoadjuvant nivolumab plus ipilimumab is safe and orchestrates de novo immune responses. The 82.5% complete response rate for primary tumors 6 months after standard chemoradiation therapy suggests favorable clinical outcomes (Abstract 5501). 

Advertisement

Advertisement




Advertisement